| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Ludwig Institute for Cancer Research, Brussels, Belgium;
Cellular Genetics Unit, Université Catholique de Louvain, Brussels, Belgium;
Cancer Immunotherapy and Gene Therapy Program, Istituto Scientifico H.S. Raffaele, Milan, Italy; and
§
Microbial Pathogenesis Unit, Institute of Cellular Pathology and Faculté de Médecine, Université Catholique de Louvain, Brussels, Belgium
MAGE genes are expressed by many human tumors of different histological types but not by normal cells, except for male germline cells. The Ags encoded by MAGE genes and recognized by T cells are therefore strictly tumor-specific. Clinical trials involving therapeutic vaccination of cancer patients with MAGE antigenic peptides or proteins are in progress. To increase the range of patients eligible for therapy with peptides, it is important to identify additional MAGE epitopes recognized by CTL. Candidate peptides known to bind to a given HLA have been used to stimulate T lymphocytes in vitro. In some instances, CTL clones directed against these synthetic peptides have been obtained, but these clones often failed to recognize tumor cells expressing the relevant gene. Therefore, we designed a method to identify CTL epitopes that selects naturally processed peptides. Monocyte-derived dendritic cells infected with a recombinant canarypoxvirus (ALVAC) containing the entire MAGE-A1 gene were used to stimulate CD8+ T lymphocytes from the blood of individuals without cancer. Responder cell microcultures that specifically lysed autologous cells expressing MAGE-A1 were cloned using autologous stimulator cells either transduced with a retrovirus coding for MAGE-A1 or infected with recombinant Yersinia-MAGE-A1 bacteria. The CTL clones were tested for their ability to lyse autologous cells loaded with each of a set of overlapping MAGE-A1 peptides. This strategy led to the identification of five new MAGE-A1 epitopes recognized by CTL clones on HLA-A3, -A28, -B53, -Cw2, and -Cw3 molecules. All of these CTL clones recognized target cells expressing gene MAGE-A1.
This article has been cited by other articles:
|
|
 |
|
  W. Li, D. K. Krishnadas, R. Kumar, D. L. J. Tyrrell, and B. Agrawal Priming and stimulation of hepatitis C virus-specific CD4+ and CD8+ T cells against HCV antigens NS4, NS5a or NS5b from HCV-naive individuals: implications for prophylactic vaccine Int. Immunol., January 1, 2008; 20(1): 89 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Slingluff Jr., G. R. Petroni, K. A. Chianese-Bullock, M. E. Smolkin, S. Hibbitts, C. Murphy, N. Johansen, W. W. Grosh, G. V. Yamshchikov, P. Y. Neese, et al. Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting Clin. Cancer Res., November 1, 2007; 13(21): 6386 - 6395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. McWilliams, S. M. McGurran, S. W. Dow, J. E. Slansky, and R. M. Kedl A Modified Tyrosinase-Related Protein 2 Epitope Generates High-Affinity Tumor-Specific T Cells but Does Not Mediate Therapeutic Efficacy in an Intradermal Tumor Model J. Immunol., July 1, 2006; 177(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Li, D. K. Krishnadas, J. Li, D. L. J. Tyrrell, and B. Agrawal Induction of Primary Human T Cell Responses against Hepatitis C Virus-Derived Antigens NS3 or Core by Autologous Dendritic Cells Expressing Hepatitis C Virus Antigens: Potential for Vaccine and Immunotherapy J. Immunol., May 15, 2006; 176(10): 6065 - 6075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. van Baren, M.-C. Bonnet, B. Dreno, A. Khammari, T. Dorval, S. Piperno-Neumann, D. Lienard, D. Speiser, M. Marchand, V. G. Brichard, et al. Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells J. Clin. Oncol., December 10, 2005; 23(35): 9008 - 9021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Luiten, E. W.M. Kueter, W. Mooi, M. P.W. Gallee, E. M. Rankin, W. R. Gerritsen, S. M. Clift, W. J. Nooijen, P. Weder, W. F. van de Kasteele, et al. Immunogenicity, Including Vitiligo, and Feasibility of Vaccination With Autologous GM-CSF-Transduced Tumor Cells in Metastatic Melanoma Patients J. Clin. Oncol., December 10, 2005; 23(35): 8978 - 8991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Chianese-Bullock, J. Pressley, C. Garbee, S. Hibbitts, C. Murphy, G. Yamshchikov, G. R. Petroni, E. A. Bissonette, P. Y. Neese, W. W. Grosh, et al. MAGE-A1-, MAGE-A10-, and gp100-Derived Peptides Are Immunogenic When Combined with Granulocyte-Macrophage Colony-Stimulating Factor and Montanide ISA-51 Adjuvant and Administered as Part of a Multipeptide Vaccine for Melanoma J. Immunol., March 1, 2005; 174(5): 3080 - 3086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Y. Chiang and I. Stroynowski A Nonclassical MHC Class I Molecule Restricts CTL-Mediated Rejection of a Syngeneic Melanoma Tumor J. Immunol., October 1, 2004; 173(7): 4394 - 4401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Breckpot, C. Heirman, C. De Greef, P. van der Bruggen, and K. Thielemans Identification of New Antigenic Peptide Presented by HLA-Cw7 and Encoded by Several MAGE Genes Using Dendritic Cells Transduced with Lentiviruses J. Immunol., February 15, 2004; 172(4): 2232 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Karanikas, C. Lurquin, D. Colau, N. van Baren, C. De Smet, B. Lethe, T. Connerotte, V. Corbiere, M.-A. Demoitie, D. Lienard, et al. Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus J. Immunol., November 1, 2003; 171(9): 4898 - 4904. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Schroers, L. Shen, L. Rollins, Z. Xiao, G. Sonderstrup, K. Slawin, X. F. Huang, and S.-Y. Chen Identification of MHC Class II-restricted T-cell Epitopes in Prostate-specific Membrane Antigen Clin. Cancer Res., August 1, 2003; 9(9): 3260 - 3271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Azuma, S. Shichijo, Y. Maeda, T. Nakatsura, Y. Nonaka, T. Fujii, K. Koike, and K. Itoh Mutated p53 Gene Encodes a Nonmutated Epitope Recognized by HLA-B*4601-restricted and Tumor Cell-reactive CTLs at Tumor Site Cancer Res., February 15, 2003; 63(4): 854 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Klein, M. Wilke, J. Pool, C. Vermeulen, E. Blokland, E. Burghart, S. Krostina, N. Wendler, B. Passlick, G. Riethmueller, et al. The Hematopoietic System-specific Minor Histocompatibility Antigen HA-1 Shows Aberrant Expression in Epithelial Cancer Cells J. Exp. Med., August 5, 2002; 196(3): 359 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. von Bergwelt-Baildon, R. H. Vonderheide, B. Maecker, N. Hirano, K. S. Anderson, M. O. Butler, Z. Xia, W. Y. Zeng, K. W. Wucherpfennig, L. M. Nadler, et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application Blood, May 1, 2002; 99(9): 3319 - 3325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Schultz, J. Chapiro, C. Lurquin, S. Claverol, O. Burlet-Schiltz, G. Warnier, V. Russo, S. Morel, F. Levy, T. Boon, et al. The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome J. Exp. Med., February 11, 2002; 195(4): 391 - 399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Motta, F. Andre, A. Lim, J. Tartaglia, W. I. Cox, L. Zitvogel, E. Angevin, and P. Kourilsky Cross-Presentation by Dendritic Cells of Tumor Antigen Expressed in Apoptotic Recombinant Canarypox Virus-Infected Dendritic Cells J. Immunol., August 1, 2001; 167(3): 1795 - 1802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Russmann, E. I. Igwe, J. Sauer, W.-D. Hardt, A. Bubert, and G. Geginat Protection Against Murine Listeriosis by Oral Vaccination with Recombinant Salmonella Expressing Hybrid Yersinia Type III Proteins J. Immunol., July 1, 2001; 167(1): 357 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Kessler, N. J. Beekman, S. A. Bres-Vloemans, P. Verdijk, P. A. van Veelen, A. M. Kloosterman-Joosten, D. C.J. Vissers, G. J.A. ten Bosch, M. G.D. Kester, A. Sijts, et al. Efficient Identification of Novel HLA-A*0201-presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen PRAME by Proteasome-mediated Digestion Analysis J. Exp. Med., January 2, 2001; 193(1): 73 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Dyall, J.-B. Latouche, S. Schnell, and M. Sadelain Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes Blood, January 1, 2001; 97(1): 114 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gnjatic, Y. Nagata, E. Jager, E. Stockert, S. Shankara, B. L. Roberts, G. P. Mazzara, S. Y. Lee, P. R. Dunbar, B. Dupont, et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele PNAS, September 26, 2000; 97(20): 10917 - 10922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Cornelis Molecular and cell biology aspects of plague PNAS, August 1, 2000; 97(16): 8778 - 8783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chames, S. E. Hufton, P. G. Coulie, B. Uchanska-Ziegler, and H. R. Hoogenboom Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library PNAS, July 5, 2000; 97(14): 7969 - 7974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Martelange, C. De Smet, E. De Plaen, C. Lurquin, and T. Boon Identification on a Human Sarcoma of Two New Genes with Tumor-specific Expression Cancer Res., July 1, 2000; 60(14): 3848 - 3855. [Abstract] [Full Text]
|
|
|
|
|
|
L. Heidecker, F. Brasseur, M. Probst-Kepper, M. Gueguen, T. Boon, and B. J. Van den Eynde Cytolytic T Lymphocytes Raised Against a Human Bladder Carcinoma Recognize an Antigen Encoded by Gene MAGE-A12 J. Immunol., June 1, 2000; 164(11): 6041 - 6045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yang, D. Kittlesen, C. L. Slingluff Jr., C. E. Vervaert, H. F. Seigler, and T. L. Darrow Dendritic Cells Infected with a Vaccinia Vector Carrying the Human gp100 Gene Simultaneously Present Multiple Specificities and Elicit High-Affinity T Cells Reactive to Multiple Epitopes and Restricted by HLA-A2 and -A3 J. Immunol., April 15, 2000; 164(8): 4204 - 4211. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
